The termination does not impact Medtronic’s fiscal year 2024 adjusted earnings per share guidance range that the company provided on November 21, 2023. Medtronic continues to advance its automated insulin dosing product pipeline, including a differentiated patch pump.
Related Posts
Trump fails to overturn E. Jean Carroll’s $83 million verdict
By Jonathan Stempel NEW YORK (Reuters) – A federal appeals court on Monday refused to throw out an $83.3 million…
Former Fed Governor Kugler’s exit came amid forbidden trading activity
By Michael S. Derby NEW YORK (Reuters) -Former Federal Reserve Governor Adriana Kugler, who abruptly resigned this summer, had multiple…
Frontier markets fail to live up to economic potential, says World Bank
LONDON, Jan 20 (Reuters) – Frontier market economies have failed to live up to their potential in recent decades, suffering…